Analysts have been eager to weigh in on the Healthcare sector with new ratings on Celgene (NASDAQ:CELG), Theravance Biopharma (NASDAQ:TBPH) and Axovant Sciences (NYSE:AXON).
Celgene (CELG)
In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Celgene, with a price target of $150. The company’s shares opened today at $85.21, close to its 52-week low of $74.13.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 16.1% and a 57.9% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Celgene is a Moderate Buy with an average price target of $119.67, representing a 40.4% upside. In a report issued on June 29, Jefferies also maintained a Buy rating on the stock with a $115 price target.
.
See today’s analyst top recommended stocks >>
Theravance Biopharma (TBPH)
In a report released yesterday, Alan Carr from Needham maintained a Buy rating on Theravance Biopharma, with a price target of $40. The company’s shares opened today at $26.69.
Carr noted:
“We will be hosting a conference call with neurologist to discuss and TD-9855. Theravance is evaluating 1/2 trial in patients with . Results are expected to be available this month.”
According to TipRanks.com, Carr is a 4-star analyst with an average return of 5.1% and a 43.5% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Theravance Biopharma with a $42 average price target.
Axovant Sciences (AXON)
Cowen & Co. analyst Ritu Baral maintained a Hold rating on Axovant Sciences yesterday. The company’s shares opened today at $2.59, close to its 52-week low of $1.02.
According to TipRanks.com, Baral is a top 25 analyst with an average return of 38.9% and a 57.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Global Blood Therapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for Axovant Sciences with a $7 average price target, a 170.3% upside from current levels. In a report issued on June 28, Chardan Capital also maintained a Hold rating on the stock.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AXON:
